Delphinus Medical Adds to Board of Directors

Delphinus Medical Technologies Inc. has welcomed Ron Ho has to its Board of Directors. 

Ho’s career has included multiple executive positions spanning more than 20 years within the medical imaging industry, predominantly in ultrasound. He was president and CEO of U-Systems Inc., developer of the somo•V automated whole breast ultrasound system.  During his tenure, the company achieved the first and only U.S. Food and Drug Administration (FDA) approval for a breast ultrasound screening indication.  Following the approval, Ho directed U-Systems through its acquisition by GE Healthcare.

“I’m excited to join the Delphinus Board of Directors,” Ho said. “New technologies are needed to improve breast cancer detection and diagnosis, particularly for women with dense breast tissue. Delphinus’ technology has the potential to advance screening for these women and also provide clinical differentiation of benign and malignant breast masses.  I believe this combination will be an important contribution to breast cancer detection.”

“We are extremely pleased that Ron is joining Delphinus’ Board of Directors,” said Board Chairman Paul McCreadie, managing director of Arboretum Ventures. “With his experience in the breast ultrasound space and success in securing a regulatory-first, we look forward to his contribution and direction. Ron’s knowledge of the market will benefit Delphinus greatly as we move forward with commercial activities.”

Delphinus claims it is the first company to design and manufacture a breast ultrasound system that utilizes ring transducer technology to transmit and receive ultrasound signals. Its SoftVue device captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. With a short scan time of one to two minutes per breast, SoftVue presents a complete image map of the whole breast, providing a consistent and uniform exam without reliance on operator skill and technique.

“We look forward to Ron’s participation on our board. He brings a strong knowledge and experience base within breast ultrasound, having gained success where others have not. We’re very enthused to have the opportunity to share in his technical, regulatory, and strategic insight, as we move ahead to fully commercialize our SoftVue technology,” said Delphinus CEO Mark Morsfield.

Delphinus Medical Technologies Inc., a Michigan-based company, developed SoftVue, the first circular array transducer technology that has received FDA clearance. The patented technology is a whole breast ultrasound tomography imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography.

Arboretum Ventures is a venture capital firm specializing in the healthcare sector. Founded in 2002, the firm manages $235 million in capital and has invested in more than 30 companies, five of which have exited with an aggregate valuation of approximately $1 billion. Arboretum invests throughout the United States, with a preference for Midwest opportunities, targeting capital efficient companies that can meaningfully reduce healthcare costs in key areas of expertise: devices, diagnostics, services, and IT.